@incollection{,
	
					
					
					9BD7332D025951C425419E8E2633C0CE
				,
	author={{Matheus AmorimGrigorio}},
	journal={{Global Journal of Medical Research}},
	journal={{GJMR}}2249-46180975-588810.34257/GJMR,
	address={Cambridge, United States},
	publisher={Global Journals Organisation}23912
}

@book{b0,
	
	
		,
	title={{Institute for Health Netrics and Evaluation}}
		
			,
	year={2017}
			,
	address={Seattle (WA}
		
		
			University of Washington
		
	
	,
	note={Global Burden of Disease (GBD}

}

@book{b1,
	
	
		,
	title={{Vigitel Brasil 2007 -Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico}}
		,
	author={{
			MinistérioBrasil
		} and {
			Da Saúde
		}}
		
		
			,
	year={2008}
			
		
	

}

@incollection{b2,
	
	
		,
	title={{}}
		
	
	
		,
	journal={{Obesity and overweight}}
		
			,
	year={2006}
			,
	publisher={World Health Organization}
		
	

}

@incollection{b3,
	
	
		,
	title={{Efeitos na saúde do sobrepeso e da obesidade em 195 países ao longo de 25 anos}}
		,
	author={{
			AAfshin
		} and {
			MHForouzanfar
		} and {
			MBReitsma
		}}
		
		
	
	
		,
	journal={{N Engl J Med}}
		
			377
			1
			
			,
	year={2017}
		
	

}

@incollection{b4,
	
	
		,
	title={{Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) rationale and design}}
		,
	author={{
			DHRyan
		} and {
			ILingvay
		} and {
			HMColhoun
		} and {
			JDeanfield
		} and {
			SSEmerson
		} and {
			SEKahn
		} and {
			RFKushner
		} and {
			SMarso
		} and {
			JPlutzky
		} and {
			KBrown-Frandsen
		} and {
			MolGronning
		} and {
			GKHovingh
		} and {
			AGHolst
		} and {
			HRavn
		} and {
			AMLincoff
		}}
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		10.1016/j.ahj.2020.07.008.Epub
		32916609
	
	
		,
	journal={{Am Heart J}}
		
			229
			
			,
	year={2020 Nov. 2020 Jul 17}
		
	

}

@incollection{b5,
	
	
		,
	title={{Efeito do Semaglutido Subcutâneo Semanal Continuado vs Placebo na Manutenção da Perda de Peso em Adultos com Sobrepeso ou Obesidade: O Ensaio Clínico Randomizado STEP 4}}
		,
	author={{
			DRubino
		} and {
			NAbrahamsson
		} and {
			MDavies
		} and {
			DHesse
		} and {
			FLGreenway
		} and {
			CJensen
		} and {
			ILingvay
		} and {
			OMosenzon
		} and {
			JRosenstock
		} and {
			MARubio
		} and {
			GRudofsky
		} and {
			STadayon
		} and {
			TAWadden
		}}
		
		
		
		
		
		
		
		
		
		
		
		
		10.1001/jama.2021.3224
		33755728
		PMC7988425
	
	
		,
	booktitle={{Dicker D; STEP 4 Investigadores}}
		
			,
	year={2021}
			13
			
		
	

}

@incollection{b6,
	
	
		,
	title={{Revisão clínica do semaglutido subcutâneo para obesidade}}
		,
	author={{
			APhillips
		} and {
			JNClements
		}}
		
		10.1111/jcpt.13574
		34964141
	
	
		,
	journal={{J Clin Pharm Ther}}
		
			47
			2
			de
			,
	year={2022. 2021}
		
	
	,
	note={Fev}

}

@incollection{b7,
	
	
		,
	title={{Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?}}
		,
	author={{
			YLi
		} and {
			PDRosenblit
		}}
		
		10.1007/s11886-018-1051-2
		30259238
	
	
		,
	journal={{Curr Cardiol Rep}}
		
			20
			11
			113
			,
	year={2018 Sep 26}
		
	

}

@incollection{b8,
	
	
		,
	title={{Agonista GLP-1 para Tratar a Obesidade e Prevenir Doenças Cardiovasculares: O Que Conseguimos até agora?}}
		,
	author={{
			MRPedrosa
		} and {
			DRFranco
		} and {
			HWGieremek
		} and {
			CMVidal
		} and {
			FBronzeri
		} and {
			CassiaDe
		} and {
			ARocha
		} and {
			LGDe Carvalho Cara
		} and {
			SLFogo
		} and {
			FGEliaschewitz
		}}
		
		
		
		
		
		
		
		
		
		10.1007/s11883-022-01062-2.Epub202231deagosto
		36044100
	
	
		,
	journal={{Curr Atheroscler Rep}}
		
			24
			11
			
			,
	year={2022 Nov}
		
	

}

@book{b9,
	
	
		,
	title={{World Health Organization [WHO] Cardiovascular diseases}}
		Acesso em 03/09/2023
		
		
			,
	year={2022}
		
	

}